Skip to main content

Table 2 Baseline demographics, apolipoprotein E status, cerebrospinal fluid markers and clinical score evolution in the longitudinal cohort (patients with significant memory complaint/mild cognitive impairment) by last known status

From: Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Last known status Normal (n = 105 [27%]) MCI (n = 209 [53%]) AD (n = 82 [21%])
Follow-up duration, months 25 ± 12 34 ± 16a 36 ± 13
Male sex 40 (38%) 121 (58%)a 43 (52%)
Age, years 71 ± 6 72 ± 7 73 ± 7
ApoE4 carriers 41 (39%) 87 (42%) 58 (71%)b
Baseline cognition
 GDS 1.1 ± 1.1 1.8 ± 1.4a 1.8 ± 14
 MMSE 29 ± 1 28 ± 2a 27 ± 2b
 CDR 0 86 (82%) 9 (4%)a 1 (1%)b
 CDR 0.5 19 (18%) 199 (95%)a 81 (99%)b
 CDR ≥1 0 1 (0.5%) 0
 ADAS-cog 9 ± 4 14 ± 6a 22 ± 7b
Baseline CSF
 Aβ1–42 (ng/L) 204 ± 48 179 ± 53a 141 ± 35b
 Tau (ng/L) 62 ± 30 77 ± 44a 121 ± 60b
 p-Tau181 (ng/L) 35 ± 20 38 ± 23 59 ± 25b
 p-Tau181/Aβ1–42 0.19 ± 0.15 0.25 ± 0.20c 0.44 ± 0.21b
Follow-up
 MMSE annual change −0.1 ± 0.2 −0.4 ± 1.1 −2 ± 2.3b
 CDR annual change 0.01 ± 0.14 0.00 ± 0.10 0.23 ± 0.21b
 ADAS-cog annual change −0.1 ± 2.3 0.5 ± 3.3 3.7 ± 3.8b
 Time to conversion, months 22 ± 13
  1. Abbreviations: Aβ Amyloid-β1–42, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale–Cognitive Subscale, ApoE Apolipoprotein E, CDR Clinical Dementia Rating, GDS Geriatric Depression Scale, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, SMC Significant memory complaint
  2. a p < 0.001 vs normal patients
  3. b p < 0.001 vs patients with MCI
  4. c p < 0.01 vs normal patients